Institute of Cancer Stem Cell, Cancer Center, Dalian Medical University, Dalian, 116044, Liaoning, P.R. China.
State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, Guangzhou, 510630, Guangdong, P.R. China.
Cancer Commun (Lond). 2018 May 4;38(1):17. doi: 10.1186/s40880-018-0287-y.
Precision medicine has shed new light on the treatment of heterogeneous cancer patients. However, intratumor heterogeneity strongly constrains the clinical benefit of precision medicine. Thus, rethinking therapeutic strategies from a different facet within the precision medicine framework will not only diversify clinical interventions, but also provide an avenue for precision medicine. Here, we explore the current approaches for targeting intratumor heterogeneity and their limitations. Furthermore, we propose a theoretical strategy with a "homogenization" feature based on iatrogenic evolutionary selection to target intratumor heterogeneity.
精准医学为异质性癌症患者的治疗带来了新的曙光。然而，肿瘤内异质性强烈限制了精准医学的临床获益。因此，从精准医学框架的不同方面重新思考治疗策略不仅可以使临床干预多样化，而且为精准医学提供了一个途径。在这里，我们探讨了目前针对肿瘤内异质性的方法及其局限性。此外，我们提出了一种基于医源性进化选择的具有“同质化”特征的理论策略，以靶向肿瘤内异质性。
Zotero 插件
